key: cord-0912807-6lgwjh00
authors: Yetmar, Zachary A.; Challener, Douglas W.; Tleyjeh, Imad M.; Sohail, M. Rizwan; Cerhan, James R.; Badley, Andrew D.; O’Horo, John C.
title: Association between Chronic Statin Use and 30-Day Mortality in Hospitalized Patients with COVID-19
date: 2021-03-14
journal: Mayo Clin Proc Innov Qual Outcomes
DOI: 10.1016/j.mayocpiqo.2021.02.002
sha: 5a2c427929070c8f82a76668babf8b0078154f0c
doc_id: 912807
cord_uid: 6lgwjh00

Objective To determine the association between chronic statin use and mortality in patients hospitalized with COVID-19. Patients and Methods We identified a retrospective cohort of patients requiring admission at the Mayo Clinic using our enterprise-wide COVID-19 registry from March 1st, 2020, through September 30th, 2020. Available information included age, gender, use of statins, medical comorbidities, and 30-day mortality. We estimated the association of statins with 30-day mortality using odds ratios (OR) and 95% confidence intervals (CI) from logistic regression modeling. Results 1295 patients between the ages of 30 and 80 tested positive for COVID-19 and required admission during the study period, of whom 500 (38.6%) were taking statins at admission. Patients taking statins were older and more likely to have diabetes mellitus or congestive heart failure. Within 30 days of diagnosis, 59 (4.6%) died. In multivariable analysis, statin users did not have statistically different odds of death within 30 days with OR of 1.14 (95% CI: 0.64-2.03, P=.67) compared to non-users. Conclusions Patients with COVID-19 taking statins had similar 30-day mortality to those not taking statins, after adjusting for relevant covariates. Although this is partly influenced by a higher prevalence of risk factors for more severe COVID-19 presentation not entirely adjusted for by the Charlson Comorbidity Index, these data would not support statins as a likely therapeutic intervention for COVID-19 in the hospital setting.

Since its emergence in Wuhan, China, SARS-CoV-2, the agent causing COVID-19, has infected more than 79 million people. 1, 2 Given the extent of the pandemic, there has been much investigation of risk factors for severe disease, mortality, and preventive strategies.

The use of statins, a class of medications commonly used to treat hyperlipidemia and atherosclerotic disease, has been a subject of debate. Statins have several properties that theoretically have an impact on the pathophysiology of COVID-19, with possible positive or negative effects on outcomes. In particular, expression of ACE2, the receptor utilized by SARS-CoV-2, is augmented by statin medications. 3, 4 However, lipid metabolism plays a role in viral replication and statins alter this process while also inhibiting the SARS-CoV-2 main protease in vitro. 5, 6 Patients with COVID-19 have a high rate of thromboembolism and statins have been identified to have antithrombotic properties and potentially reduce this risk. [7] [8] [9] Statins also display anti-inflammatory properties through a number of actions, including downregulation of toll-like receptors and inhibition of T-cell activation. 10, 11 These effects may improve a dysregulated inflammatory response; however, studies have been mixed on the effect of statins in influenza, 12, 13 acute respiratory distress syndrome, 14, 15 and sepsis. 16 Furthermore, several factors for severe COVID-19 are strongly associated with use of statin therapy such as older age, male gender, systemic hypertension, and cardiovascular disease. 11,17-20 Aspirin, another medication commonly prescribed for patients taking statins, is also postulated to affect outcomes in COVID-19. 21, 22 Our group has previously analyzed published data about statins and effect in infections 23 and community acquired pneumonia (CAP). 24 Data from nine cohorts addressed the role of prior statins in patients with different infections with a pooled adjusted risk ratio of 0.55 (95% confidence interval, 0.36-0.83; I 2 = 76.5%) were in favor of statins. 23 In another meta-analysis of 13 observational studies, we observed that prior statins were associated with a lower short-term mortality in patients with CAP, OR J o u r n a l P r e -p r o o f Yetmar 5 0.68 (95% CI, 0.59-0.78, I 2 = 75.7%). 24 However, a recent systematic review and meta-analysis analyzed 14 randomized controlled trials utilizing statin initiation as an adjunctive treatment for hospitalized adults with sepsis. De novo statin therapy did not reduce 30-day all-cause mortality in all patients (risk ratio (RR) 0.96, 95% confidence interval (CI) 0.83-1.10), nor in a subgroup of patients with severe sepsis (RR 0.97, 95% CI 0.84-1.12). 25 The association between statin use and outcomes of patients with COVID-19 has been recently examined in multiple studies with conflicting results. [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Therefore, we sought to examine the association of chronic statin use and COVID-19 outcome in a large hospitalized cohort from the multicenter Mayo Clinic COVID-19 registry.

Early in the pandemic, an institutional registry was created to identify patients who were intensity statins included atorvastatin 10-20 mg daily, fluvastatin 40 mg twice daily, lovastatin 40 mg daily, pitavastatin 2-4 mg daily, pravastatin 40-80 mg daily, rosuvastatin 5-10 mg daily, and simvastatin 20-40 mg daily. All lower-dosed statins were included in the low-intensity group. 36 Patients with record of statin prescription but without dosage data were excluded from the analysis that examined the association of different statin intensity and mortality. The cohort was restricted to those aged 30 to 80 years at the time of COVID-19 diagnosis to limit confounding by age, as patients outside of this range are unlikely to be prescribed statins. We also limited to those requiring hospitalization to avoid exclusion of asymptomatic or mild cases that did not undergo testing. All patients were followed for 30 days after diagnosis. Some patients did not have complete data on statin intensity (N=42, 8%); otherwise there was no missing data in this database. As this was a retrospective chart review, the IRB granted waiver of consent, and Minnesota patients without research authorization were excluded.

The associations of statin use at diagnosis with risk of death within 30 days of diagnosis were estimated using odds ratios (OR) and 95% confidence intervals from logistic regression modeling. Our multivariable model was adjusted for 10-CCI, gender, COVID-19 treatment trial enrollment, and aspirin use. 10-CCI was chosen as it incorporates many variables associated with outcomes in COVID-19 such as age and comorbidities. We did perform an exploratory subgroup analysis of this model by separating statin use by intensity. Patients without statin intensity data (N=41/500 with statin use, 8%) were excluded from this subgroup analysis. All analyses were performed using JMP Pro 14.0 (SAS Institute Inc., Cary, NC).

We identified 1295 patients hospitalized with COVID-19 through September 30 th . At diagnosis, 500 (38.6%) were identified as prescribed a statin. In the total cohort, 114 (8.8%) patients had received a diagnosis of congestive heart failure (CHF), 390 (30.1 %) diabetes mellitus (DM), and 90 (6.9%) coronary J o u r n a l P r e -p r o o f Yetmar 7 artery disease (CAD). Three-hundred eighty-four (29.7%) patients were taking any dose of aspirin prior to admission. Patients on a statin were older, more likely to be male, had a much higher prevalence of DM, CHF, CAD, and aspirin use. These patients also had a lower 10-CCI. Patient characteristics by statin use are shown in table 1.

Within 30 days of diagnosis, 59 (4.6%) of patients had died. This included 35 (7%) patients with statins and 24 (3%) patients without statins. After adjusting for 10-CCI, gender, clinical trial enrollment, and aspirin use, patients taking statins did not have a statistically different odds for 30-day mortality compared to non-users (OR=1.14; 95% CI: 0.64-2.03, P=.67). In the subset of patient in which statin intensity dosing was available, a separate analysis was performed with statin intensity as predictors. The odds ratios were similar for each dose of statin and the quality of the model was lower than the model using statin as a binary predictor, as indicated by significantly increased Akaike information criterion.

There remains a desperate need to determine optimal strategies for managing patients with COVID-19. While many new treatment regimens are being developed, the effect of existing medications should continue to be evaluated for efficacy or harm. Statins have plausible mechanisms for both improving and worsening outcomes in COVID-19 while also being widely used. However, our study did not identify a difference in odds of 30-day mortality for statin users, regardless of the intensity of statin therapy.

While our cohort had inferior 30-day crude mortality on statins, much of this appeared to be related to confounding as many indications for statins are risk factors for more severe disease from [17] [18] [19] [20] Indeed, after adjustment for 10-CCI, gender, clinical trial enrollment, and aspirin use, there was essentially no association of statin use with 30-day mortality. A prior study indicated that glycemic control correlated with outcomes in COVID. 37 It would follow that diabetic medications act J o u r n a l P r e -p r o o f Yetmar 8 both as a marker of illness and a marker for higher likelihood of controlled illness. Thus, diabetes medications may correlate with both positive and negative effects. Similarly, continuing statins in those with an indication may also contribute to controlling these risk factors for more severe COVID-19.

However, it should be noted that interferon responses play a critical role in controlling SARS-CoV-2 38 and statins appear to impair the interferon response. 39 Our study has several limitations worth noting. The retrospective nature of our review likely has inherent sources of bias. We also had an overall low number of patients meeting some outcomes, such as 30-day mortality. Another limitation of this study is potential misclassification of patient attributes as these were based on billing codes. Our registry also did not include complete data on the type or dosage of statin medication. This limited our analysis of statin intensity's potential effect on mortality. Finally, our data do not directly answer the question of whether starting a statin at diagnosis of COVID-19 would impact outcomes.

Ultimately, we did not identify statin users as having a higher or lower odds of 30-day mortality as compared to non-users. In the context of the previously noted limitations, this study does not support statin initiation or discontinuation as a therapeutic intervention in patients with COVID-19.

J o u r n a l P r e -p r o o f 

Guide to Understanding the 2019 Novel Coronavirus

Coronavirus disease (COVID-19) Weekly Epidemiological Update -29

COVID-19, ACE2, and the cardiovascular consequences

Potential role of statins in COVID-19

The role of lipid metabolism in COVID-19 virus infection and as a drug target

Statins and the Covid-19 main protease: In silico evidence on direct interaction

Venous Thromboembolism in COVID-19 ICU Patients

Statins as antithrombotic drugs

A randomized trial of rosuvastatin in the prevention of venous thromboembolism

Are statins safe in patients with COVID-19?

Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review

Influenza Morbidity and Mortality in Elderly Patients Receiving Statins: A Cohort Study

Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: A multistate study

Simvastatin in the acute respiratory distress syndrome

ARDS Subphenotypes and Differential Response to Simvastatin: Secondary Analysis of a Randomized Controlled Trial

Randomized double-blind placebo

mg/day of atorvastatin in reducing the severity of sepsis in ward patients

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study

Covid-19: Risk factors for severe disease and death

Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China

Inpatient Care of Patients with COVID-19: A Guide for Hospitalists

Aspirin Use is Associated with Decreased Mechanical Ventilation, ICU Admission, and In-Hospital Mortality in Hospitalized Patients with COVID-19

Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?

Statins for the Prevention and Treatment of Infections

The Role of Statins in Prevention and Treatment of Community Acquired Pneumonia: A Systematic Review and Meta-Analysis

Hydroxymethylglutaryl-CoA reductase inhibitors (statins) for the treatment of sepsis in adults -A systematic review and meta-analysis

In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19

EFFECT OF STATIN THERAPY ON SARS-CoV-2 INFECTION-RELATED MORTALITY IN HOSPITALIZED PATIENTS

Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients

Protective role of statins in COVID 19 patients: importance of pharmacokinetic characteristics rather than intensity of action

Statin use is associated with decreased risk of invasive mechanical ventilation in COVID-19 patients: A preliminary study

Statin Use and In-Hospital Mortality in Diabetics with COVID-19

Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection

Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes: Results from the CORONADO study

Atorvastatin associated with decreased hazard for death in COVID-19 patients admitted to an ICU: a retrospective cohort study

The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia : Part 1 -Full Report

Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes

Inborn errors of type I IFN immunity in patients with lifethreatening COVID-19. Science (80-)

Statins attenuate antiviral IFN-β and ISG expression via inhibiting IRF3/JAK/STAT signaling in poly(I:C)-treated hyperlipidemic mice and macrophages. bioRxiv

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

Please enter your first and last name, and double-check the manuscript number and title.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party --that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work. Date Submitted: 02/16/2021

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc…)? Complete each row by checking "No" or providing the requested information.